A method for preparing an ophthalmic device for slowing, inhibiting or preventing myopia progression involves (a) soaking an ophthalmic device in one or more first solvent solutions to swell the ophthalmic device; (b) soaking the swelled ophthalmic device in one or more second solvents solutions comprising one or more red-light blocking compounds blocking greater than about 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nanometers (nm) to about 800 nm to de-swell the swelled ophthalmic device and entrap the one or more red-light blocking compounds in the de-swelled ophthalmic device; and (c) sterilizing the de-swelled ophthalmic device.

A method for preparing an ophthalmic device for slowing, inhibiting or preventing myopia progression involves (a) soaking an ophthalmic device in one or more first solvent solutions to swell the ophthalmic device; (b) soaking the swelled ophthalmic device in one or more second solvents solutions comprising one or more red-light blocking compounds blocking greater than about 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nanometers (nm) to about 800 nm to de-swell the swelled ophthalmic device and entrap the one or more red-light blocking compounds in the de-swelled ophthalmic device; and (c) sterilizing the de-swelled ophthalmic device.

The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, mucoprotein, lipoprotein, glycoprotein, or polynucleotide; and (2) a polymer comprising a pharmaceutical agent. The conjugates may be useful in delivering (e.g., targeted delivering) the pharmaceutical agent to a subject in need thereof or cell or treating, preventing, or diagnosing a disease.

The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, mucoprotein, lipoprotein, glycoprotein, or polynucleotide; and (2) a polymer comprising a pharmaceutical agent. The conjugates may be useful in delivering (e.g., targeted delivering) the pharmaceutical agent to a subject in need thereof or cell or treating, preventing, or diagnosing a disease.

The present invention pertains to a composition comprising: (I) at least one ionic liquid of formula (1-a) or of formula (1-b): [RF-CFR′.sub.F-SO.sub.3].sup.− A.sup.+ (1-a) [(RF-CFR′F—SO.sub.2).sub.2N].sup.− (1-b) wherein: -R.sub.F is a C.sub.1-C.sub.25 fluoroalkyi group, optionally comprising one or more than one catenary ethereal oxygen atoms, -R′.sub.F is —F or a —CF.sub.3 group, and -A+ is an organic cation selected from the group consisting of tetraalkylammonium, pyridinium, imidazolium, piperidinium, pyrrolidinium, amidinium and guanidinium groups, and (II) at least one metal salt of formula (II): MeB, (H) wherein: -Me.sup.m+ is a metal cation deriving from a metal (Me) selected from the group consisting of groups IB, MB, IVB, VB, VIB, MIA, IVA and VIII (8, 9, 10) of the Periodic Table, preferably from the group consisting of groups IVB, VB, VIB and IMA of the Periodic Table, wherein m is the valence of said metal cation, and —B.sup.n− is an inorganic anion, wherein n is the valence of said inorganic anion. The present invention also pertains to the use of said composition in an electrodeposition process and to the metal-coated assembly thereby provided.

The present invention pertains to a composition comprising: (I) at least one ionic liquid of formula (1-a) or of formula (1-b): [RF-CFR′.sub.F-SO.sub.3].sup.− A.sup.+ (1-a) [(RF-CFR′F—SO.sub.2).sub.2N].sup.− (1-b) wherein: -R.sub.F is a C.sub.1-C.sub.25 fluoroalkyi group, optionally comprising one or more than one catenary ethereal oxygen atoms, -R′.sub.F is —F or a —CF.sub.3 group, and -A+ is an organic cation selected from the group consisting of tetraalkylammonium, pyridinium, imidazolium, piperidinium, pyrrolidinium, amidinium and guanidinium groups, and (II) at least one metal salt of formula (II): MeB, (H) wherein: -Me.sup.m+ is a metal cation deriving from a metal (Me) selected from the group consisting of groups IB, MB, IVB, VB, VIB, MIA, IVA and VIII (8, 9, 10) of the Periodic Table, preferably from the group consisting of groups IVB, VB, VIB and IMA of the Periodic Table, wherein m is the valence of said metal cation, and —B.sup.n− is an inorganic anion, wherein n is the valence of said inorganic anion. The present invention also pertains to the use of said composition in an electrodeposition process and to the metal-coated assembly thereby provided.

The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, mucoprotein, lipoprotein, glycoprotein, or polynucleotide; and (2) a polymer comprising a pharmaceutical agent. The conjugates may be useful in delivering (e.g., targeted delivering) the pharmaceutical agent to a subject in need thereof or cell or treating, preventing, or diagnosing a disease.

The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, mucoprotein, lipoprotein, glycoprotein, or polynucleotide; and (2) a polymer comprising a pharmaceutical agent. The conjugates may be useful in delivering (e.g., targeted delivering) the pharmaceutical agent to a subject in need thereof or cell or treating, preventing, or diagnosing a disease.

The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, mucoprotein, lipoprotein, glycoprotein, or polynucleotide; and (2) a polymer comprising a pharmaceutical agent. The conjugates may be useful in delivering (e.g., targeted delivering) the pharmaceutical agent to a subject in need thereof or cell or treating, preventing, or diagnosing a disease.

The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, mucoprotein, lipoprotein, glycoprotein, or polynucleotide; and (2) a polymer comprising a pharmaceutical agent. The conjugates may be useful in delivering (e.g., targeted delivering) the pharmaceutical agent to a subject in need thereof or cell or treating, preventing, or diagnosing a disease.